Abstract:BACKGROUND:Currently, there is no standard context that conforms to the Chinese national framework for evaluating medical decisions regarding the treatment of lung cancer.METHODS:This draft was formulated after a systematic review and a focus group discussion among 20 experts, who were senior physicians with extensive clinical experience from the Chinese Thoracic Oncology Group (CTONG) task force. Subsequently, a draft and a five-point Likert scale were sent to 300 CTONG working group members. These were modified according to feedback from a four-round modified Delphi approach. Hence, the first version of the 'Therapeutic option of lung cancer: CTONG scoring system' was formulated. Afterward, a corresponding questionnaire was designed to collect opinions on the weight allocation of various indicators. This was issued through the WeChat platform, "Oncology News" application and e-mails from October 23, 2020, to November 25, 2020. Participants from numerous occupations in cancer-related fields from various regions of China were included in the study. Overall and subgroup analyses regarding weight allocations were performed. The differences between participant-allocated and reference weights were considered to adjust the framework.RESULTS:The framework contained four aspects and six indicators, including efficacy [progression-free survival (PFS)/overall survival (OS) and subsequent treatment], safety [treatment-related severe adverse event (SAE), dose adjustment], quality of life (Qol), and compensation. The reference weights were 50%, 5%, 10%, 5%, 10%, and 20% for each indicator. By November 25, 2020, 1,043 valid questionnaires had been obtained. The majority of the questionnaires were completed by physicians (86.5%). Subgroup analysis among the various groups showed an overall consistent trend. Besides, significant differences between the participant-allocated and reference weights were found among PFS/OS (difference: -11.5%), compensation (difference: -10.1%), and subsequent treatment (difference: 9.7%) indicators. After discussion, the final weight allocations were set at 45%, 10%, 15%, 5%, 10%, and 15% for PFS/OS, subsequent treatment, treatment-related SAE, dose adjustment, Qol, and compensation, respectively.CONCLUSIONS:The CTONG scoring system, as an objective evaluation model that involves multiple parameters, is a breakthrough method for evaluating the therapeutic value of lung cancer treatment options in China, which is worthy of further verification in future clinical practice.

The clinical thinking about general treatment of lung cancer

The Chinese Thoracic Oncology Group (CTONG) Therapeutic Option Scoring System: a Multiple-Parameter Framework to Assess the Value of Lung Cancer Treatment Options

Clinical Study on the Effect of Hypofractionated Three -Dimensional Conformal Radiation Therapy in the Treatment of Non -Small Cell Lung Cancer

Clinical Thinking of Drug Therapy Decisions

Treatment for Brain Metastases from EGFR Mutations NSCLC Patients:How Should We Choose in Clinical Practice?

Expert Consensus on Treatment for Stage III Non‐small Cell Lung Cancer

The Curative Effect Observation of Treating Local Advanced Non-Small Cell Lung Cancer with 3D-CRT

Thinking of Guiding the Diagnosis of Malignant Tumor by Using Theory of Defense, Qi, Nutrient and Blood

Prognosis of Three Dimensional Conformal Radiotherapy of Locally Advanced Non-small Cell Lung Cancer with Involved-field

Philosophical Thinking over the Multidisciplinary Comprehensive Treatment of Pancreatic Cancer

Clinical path of diagnosis and treatment for locally recurrent rectal cancer

Training on Clinical Thinking to Improve Clinicians' Skills of Disease Diagnosis and Management

Thinking in the confusion, advancing in the challenges:hotspots in the comprehensive treatment of pancreatic carcinoma

Personal Opinion on Improving the Outcome of Treatment for Liver Cancer

Standardized treatment of oral cancer under the guidance of clinical practice guidelines of National Comprehensive Cancer Network

Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]

Some Issues on Chemotherapy for Advanced Non-Small Cell Lung Cancer

Academic thoughts of LIU Lu-ming in treating pancreatic cancer according to the treatment in accordance with general trend

Advancements in radiotherapy for lung cancer in China

Early Screening and Management of Lung Cancer:A Weapon to Solve the Problem of Lung Cancer in China